Update shared on30 Jul 2025
Fair value Increased 6.45%The upward revision in Indoco Remedies’ price target is primarily driven by significantly improved forecasts for revenue growth and a higher expected future P/E, resulting in the consensus price target increasing from ₹244.25 to ₹260.00.
What's in the News
- Indoco Remedies will hold a board meeting to consider and approve unaudited financial results for the quarter ended June 2025.
- Indoco's UK subsidiary launched Ticagrelor film-coated tablets 90mg in the UK, to be marketed and distributed by Clarity Pharma.
- The company received final USFDA approval for Allopurinol Tablets USP 200mg as a generic equivalent to Zyloprim 200mg, to be manufactured in Goa, India.
- The board recommended a dividend of INR 0.20 per share for FY 2024-2025, subject to shareholder approval.
- A board meeting was held to consider and approve audited financial results for the quarter and year ended March 2025, and to recommend a final dividend.
Valuation Changes
Summary of Valuation Changes for Indoco Remedies
- The Consensus Analyst Price Target has risen from ₹244.25 to ₹260.00.
- The Future P/E for Indoco Remedies has significantly risen from 8.78x to 10.13x.
- The Consensus Revenue Growth forecasts for Indoco Remedies has significantly risen from 13.6% per annum to 15.0% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.